A significant 2026 market evolution is the aggressive expansion of S1P receptor modulators into the field of gastroenterology. In 2026, the use of these drugs for Ulcerative Colitis (UC) has transitioned from an "alternative option" to a front-line therapy for moderate-to-severe cases. Clinical data released in early 2026 suggests that the "oral small molecule" advantage is particularly strong...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
English
French
Spanish
Portuguese
Italiano
Romaian
china